연구동향 분석

Efficacy of Seven-Day Potassium-Competitive Acid Blocker-Based First-Line Helicobacter Pylori Eradication Therapy Administered with Bismuth

이선영 김지연 김효빈 김정환 성인경 박형석 2021년

논문상세정보
인용/피인용
' Efficacy of Seven-Day Potassium-Competitive Acid Blocker-Based First-Line Helicobacter Pylori Eradication Therapy Administered with Bismuth' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • bismuth
  • eradication
  • helicobacter pylori
  • proton pump inhibitor
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
331 0

0.0%

' Efficacy of Seven-Day Potassium-Competitive Acid Blocker-Based First-Line Helicobacter Pylori Eradication Therapy Administered with Bismuth' 의 참고문헌

  • 위염 Kyoto 분류의 내시경 소견
    김광하 [2019]
  • Vonoprazan-based triple therapy is effective for Helicobacter pylori eradication irrespective of clarithromycin susceptibility
    Okubo H [2020]
  • Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication : a phase III, randomised, double-blind study
    Murakami K [2016]
  • Vonoprazan 10 mg daily is effective for the treatment of patients with proton pump inhibitor-resistant gastroesophageal reflux disease
    Shinozaki S [2017]
  • Validation of western Helicobacter pylori IgG antibody assays in Korean adults
    Lee SY [2015]
  • The life and death of Helicobacter pylori
    Scott D [1998]
  • The histologic detection of Helicobacter pylori in seropositive subjects is affected by pathology and secretory ability of the stomach
    Kim JH [2018]
  • Systematic review with metaanalysis : the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication
    Jung YS [2017]
  • Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment : a multicentre randomised trial in Japan
    Suzuki S [2020]
  • Second-line Helicobacter pylori eradication : a randomized comparison of 1-week or 2-week bismuth-containing quadruple therapy
    Chung JW [2011]
  • Role of bismuth in improving Helicobacter pylori eradication with triple therapy
    Dore MP [2016]
  • Randomised phase 3 trial : tegoprazan, a novel potassium-competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis
    Lee KJ [2019]
  • Randomised clinical trial : safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of tegoprazan(CJ-12420), a novel potassium-competitive acid blocker, in healthy male subjects
    Han S [2019]
  • Primary and secondary antibiotic resistance of Helicobacter pylori in Korea from 2003 to 2018
    Lee JY [2019]
  • Online registry for nationwide database of Helicobacter pylori eradication in Korea : correlation of antibiotic use density with eradication success
    Kim BJ [2019]
  • Non-bismuth and bismuth quadruple therapies based on previous clarithromycin exposure are as effective and safe in an area of high clarithromycin resistance : a real-life study
    Romano M [2020]
  • New single capsule of bismuth, metronidazole and tetracycline given with omeprazole versus quadruple therapy consisting of bismuth, omeprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients : a Chinese prospective, randomized, multicentre trial
    Xie Y [2018]
  • Isogenic variation of Helicobacter pylori strain resulting in heteroresistant antibacterial phenotypes in a single host in vivo
    Lee YC [2005]
  • Impact of previous exposure to macrolide antibiotics on Helicobacter pylori infection treatment outcomes
    Boltin D [2019]
  • How to effectively use bismuth quadruple therapy : the good, the bad, and the ugly
    Graham DY [2015]
  • High prevalence of Helicobacter pylori clarithromycin resistance mutations among Seattle patients measured by droplet digital PCR
    Talarico S [2018]
  • Helicobacter pylori eradication with proton pump inhibitors or potassium-competitive acid blockers : the effect of clarithromycin resistance
    Matsumoto H [2016]
  • Fourteen-vs seven-day bismuth-based quadruple therapy for secondline Helicobacter pylori eradication
    Hwang JJ [2015]
  • Efficacy of vonoprazanbased triple therapy for Helicobacter pylori eradication : a multicenter study and a review of the literature
    Tanabe H [2017]
  • Efficacy of bismuth added to standard triple therapy as the first-line eradication regimen for Helicobacter pylori infection
    Kim YJ [2021]
  • Efficacy of Tegoprazan for Improving the Susceptibility of Antimicrobial Agents against Antibiotic-Resistant Helicobacter pylori
  • Efficacy and safety of vonoprazan-based versus proton pump inhibitor-based triple therapy for Helicobacter pylori eradication : a metaanalysis of randomized clinical trials
    Lyu QJ [2019]
  • Efficacy and safety of twice a day, bismuth-containing quadruple therapy using highdose tetracycline and metronidazole for second-line Helicobacter pylori eradication
    Kim JY [2020]
  • Effects of patient age and choice of antisecretory agent on success of eradication therapy for Helicobacter pylori infection
    Nishizawa T [2017]
  • Dual therapy with vonoprazan and amoxicillin is as effective as triple therapy with vonoprazan, amoxicillin and clarithromycin for eradication of Helicobacter pylori
    Furuta T [2020]
  • Comparison of 7-and 14-day eradication therapy for Helicobacter pylori with first-and secondline regimen : randomized clinical trial
    Kim TH [2020]
  • Combination of bismuth and standard triple therapy eradicates Helicobacter pylori infection in more than 90% of patients
  • Bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection : effect of treatment duration and antibiotic resistance on the eradication rate in Korea
    Lee BH [2010]
  • Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy
    Zhang W [2015]
  • Assessment of Endoscopic Gastric Atrophy according to the Kimura-Takemoto Classification and Its Potential Application in Daily Practice